Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis by Scicchitano, Bianca Maria (ORCID:0000-0002-9599-6642) et al.
Scicchitano et al. Cancer Cell Int  (2018) 18:136  
https://doi.org/10.1186/s12935-018-0626-8
PRIMARY RESEARCH
Levetiracetam enhances 
the temozolomide effect on glioblastoma stem 
cell proliferation and apoptosis
Bianca Maria Scicchitano1* , Silvia Sorrentino1, Gabriella Proietti1, Gina Lama1, Gabriella Dobrowolny2, 
Angela Catizone2, Elena Binda3, Luigi Maria Larocca4 and Gigliola Sica1
Abstract 
Background: Glioblastoma multiforme (GBM) is a highly aggressive brain tumor in which cancer cells with stem cell-
like features, called cancer stem cells (CSCs), were identified. Two CSC populations have been previously identified in 
GBM, one derived from the GBM area called enhanced lesion (GCSCs) and the other one from the brain area adjacent 
to the tumor margin (PCSCs) that greatly differ in their growth properties and tumor-initiating ability. To date the most 
effective chemotherapy to treat GBM is represented by alkylating agents such as temozolomide (TMZ), whose activity 
can be regulated by histone deacetylases (HDACs) inhibitors through the modulation of O6-methylguanine-DNA 
methyltransferase (MGMT) expression. Levetiracetam (LEV), a relatively new antiepileptic drug, modulates HDAC levels 
ultimately silencing MGMT, thus increasing TMZ effectiveness. However, an improvement in the therapeutic efficacy 
of TMZ is needed.
Methods: Cell proliferation was investigated by BrdU cell proliferation assay and by Western Blot analysis of PCNA 
expression. Apoptosis was evaluated by Western Blot and Immunofluorescence analysis of the cleaved Caspase-3 
expression. MGMT and HDAC4 expression was analyzed by Western Blotting and Immunofluorescence. Statistical 
analysis was performed using the Student’s t test and Mann–Whitney test.
Results: Here we evaluated the effect of TMZ on the proliferation rate of the IDH-wildtype GCSCs and PCSCs derived 
from six patients, in comparison with the effects of other drugs such as etoposide, irinotecan and carboplatin. Our 
results demonstrated that TMZ was less effective compared to the other agents; hence, we verified the possibility to 
increase the effect of TMZ by combining it with LEV. Here we show that LEV enhances the effect of TMZ on GCSCs 
proliferation (being less effective on PCSCs) by decreasing MGMT expression, promoting HDAC4 nuclear translocation 
and activating apoptotic pathway.
Conclusions: Although further studies are needed to determine the exact mechanism by which LEV makes GBM 
stem cells more  sensitive to TMZ, these results suggest that the clinical therapeutic efficacy of TMZ in GBM might be 
enhanced by the combined treatment with LEV.
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Background
Glioblastoma multiforme (GBM) is one of the most 
aggressive primary brain tumor. It has been demon-
strated that mutations of the IDH1 gene correlate with 
outcome in patients with malignant glioma and are 
considered as independent factors for predicting longer 
overall survival and progression free survival in patients 
with GBM [1]. In GBM, cancer cells with stem cell-like 
features, called cancer stem cells (CSCs), were identified 
[2, 3]. GBM stem-like cells (GSCs) have a high capacity to 
resist or to adapt to standard therapies which include sur-
gery followed by radiotherapy and chemotherapy [4–6], 
resulting in a poor prognosis with a median survival time 
of about 14 months [7, 8]. Thus, the development of effi-
cient strategies targeting these cells  is urgently needed.
It has been demonstrated that CSC distinct pools 
reside within different regions of the same GBM [9–11]. 
More recently, the presence of two GSC populations, 
one derived from the GBM area called enhanced lesion 
(GCSCs) and the other one from the brain area adjacent 
to the tumor margin (PCSCs) that greatly differ in their 
growth properties and tumor-initiating ability,  was iden-
tified. Indeed, GCSCs and PCSCs possess key neural stem 
cell features, such as multipotency, clonogenic ability and 
extensive self-renewal, together with aberrant growth 
properties [12]. Moreover, the area adjacent to the tumor 
shows edema, vascular alterations [13, 14], reactive astro-
cytes and microglia [15, 16] in addition to  an abnormal 
gene expression  [17, 18]. It has been demonstrated that 
tumor recurrence occurs in tissue neighboring GBM in 
approximately 90% of patients, suggesting a growing rel-
evance for this area in translational research [16, 19].
GSCs can be isolated from surgical specimens through 
mechanical dissociation of the tumor tissue and culture 
in a serum-free medium. In this conditions GCSC- and 
PCSC-derived cell clones are able to grow in  vitro in 
aggregates called neurospheres and maintain an undif-
ferentiated state as demonstrated by the expression of 
stem cell markers. Moreover, when injected in immuno-
suppressed mice, these cells are able to generate a tumor 
identical to the original one in terms of antigen expres-
sion and histological features, although GCSCs exhibit 
a higher tumor-initiating ability and clonogenicity when 
compared with PCSCs [12]. For all the above, GCSCs 
and PCSCs represent a good model to study glioblas-
toma response to treatments and, in particular, to high-
light the role of neighboring microenvironment in tumor 
progression. To date the most effective chemotherapies 
to treat GBM are alkylating agents such as Temozolo-
mide (TMZ), with a good penetration into the blood–
brain barrier [20]. Alkylating agents damage DNA by 
formation of different small and  bulky adducts with 
nucleic acid bases. In particular, TMZ acts by delivering 
a methyl group to purine bases of DNA leading to cell 
cycle arrest and, eventually, to apoptosis [21]. O6-Meth-
ylguanine-DNA-methyltransferase (MGMT) repairs the 
most cytotoxic lesions generated by TMZ, by remov-
ing the methyl adducts from DNA. MGMT promoter 
methylation, leading to a transcriptional silencing, cor-
relates with improved survival in GBM patients exposed 
to alkylating agent treatment. Accordingly, expression 
of MGMT is one of the most robust predictors of the 
TMZ response in malignant glioma cells [22–24]. Epige-
netic mechanisms are increasingly recognized as a major 
factor contributing to pathogenesis of cancer includ-
ing glioblastoma. Enzymatic modification of histone 
proteins regulating gene expression are recently being 
exploited for therapeutic drug targeting. In particular, 
histone acetylation and deacetylation have been demon-
strated to regulate several physiological and pathological 
cellular processes. Histone acetylation is mediated by 
histone acetyltransferases (HATs) and generally allows 
for active gene transcription. Conversely, histone dea-
cetylation is catalyzed by histone deacetylases (HDACs) 
and favors gene repression. Eighteen distinct HDACs 
have been identified so far and they are classified into 
four classes based on their sequence and catalytic activ-
ity. HDAC4 is a member of class II and it has been dem-
onstrated to be involved in progression of GBM [25]. 
In addition, it has been recently   reported that a great 
number of non-histone proteins can undergo reversible 
acetylation by HATs and HDACs. Modifications in this 
dynamic equilibrium can disturb cell homeostasis and 
result in a pathological state [26]. Nevertheless, HDAC 
inhibitors cause acetylation of both histone and non-his-
tone proteins and exert multiple anti-tumoral effects by 
inducing differentiation, apoptosis, cell cycle arrest, sus-
ceptibility to chemotherapy and inhibition of migration 
and angiogenesis [27].
Emerging evidences demonstrate that some antie-
pileptic drugs (AEDs) have a transcriptional regulatory 
activity via HDAC modulation [28]. In particular, it 
has been shown that Levetiracetam (LEV), a relatively 
new AED, increases the transcription of HDACs and 
recruits corepressor complex on MGMT promoter, 
thus silencing its activity [22].
In this work, we used the GCSC and the PCSC neu-
rospheres derived from primary GBM of six patients, 
according to the WHO 2016 classification, and we evalu-
ated the effect of several antineoplastic drugs such as 
TMZ, Etoposide (ETO), Irinotecan (IRI) and Carboplatin 
(CARB) on their proliferation. Since our results demon-
strated that the chemotherapeutic agent with less efficacy 
was TMZ, we subsequently investigated the possibility to 
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increase its cytotoxic activity by the concomitant treat-
ment with LEV.
Here we show that LEV enhances the effect of TMZ 
on GCSCs proliferation (being less effective on PCSCs) 
by decreasing MGMT expression, promoting HDAC4 
nuclear translocation and activating apoptotic pathway. 
Although further studies are needed to determine the 
exact mechanism by which LEV sensitizes GBM stem 
cells to TMZ, these results suggest that the clinical ther-
apeutic efficacy of TMZ in GBM might be enhanced by 
the combination treatment with LEV.
Materials and methods
Neurosphere culture
A total of six pairs of neurospheres derived from both 
GBM and peritumoral tissue (at a distance < 1  cm from 
macroscopic tumor border), called Glioblastoma Cancer 
Stem Cells (GCSCs) and Peritumoral Cancer Stem Cells 
(PCSCs), respectively, were kindly provided by Vescovi 
and Binda. According to the classification of human gli-
omas by WHO [29], we analyzed the GCSC and PCSC 
neurospheres for the mutational status of IDH1 [30, 31]. 
Mutational IDH1/2 status and MGMT promoter methyl-
ation status were also investigated in all the available tis-
sue samples from which the neurospheres were derived 
[32].
The neurospheres were cultured in NeuroCult™ NS-A 
Proliferation Kit (StemCell Technologies Inc, Vancou-
ver, BC, Canada) supplemented with 20  ng/mL human 
recombinant EGF, 10  ng/ml human recombinant bFGF 
and 2  µg/mL heparin (all from StemCell Technologies 
Inc.), as described previously [33]. All cell cultures were 
maintained at 37 °C in a 5% CO2 humidified atmosphere.
IDH analysis
IDH1 was amplified from 20  ng genomic DNA with 
forward primer 5′- ACC AAA TGG CAC CAT ACG A-3′ 
and reverse primer 5′- TTC ATA CCT TGC TTA ATG 
GGTGT-3′ using conditions described by Balss J. et  al. 
[34]. The resulting PCR products were sequenced using 
the ABI Prism BigDye Terminator v3.1 Cycle Sequenc-
ing Kit (Applied Biosystems, 4337455). Thirty cycles 
were performed employing 10 mM of the sense primers 
with denaturing at 95 °C for 10 s, annealing at 56 °C for 
5 s and extension at 60  °C for 240 s. A second round of 
sequencing analysis was performed using the antisense 
primer. Sequences were determined using the automated 
AB3130xl (Applied Biosystems, CA, USA). Results were 
analyzed with Chromas Lite software (Technelysium) 
and Mutation Surveyor software (SoftGenetics).
O6‑Methylguanine‑DNA methyltransferase (MGMT) 
promoter methylation analysis
O6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation patterns were studied by methyl-
ation-specific PCR using primers specific for methylated 
and unmethylated DNA [35] on genomic DNA extracted 
from paraffin-embedded tissue using QIAamp DNA 
Mini kit (Qiagen). The annealing temperature was 60 °C. 
DNA from normal lymphocytes treated with SssI meth-
yltransferase (New England Biolabs) was used as a posi-
tive control for methylated and unmethylated alleles of 
MGMT. PCR products were separated onto 3% agarose 
gel, stained with ethidium bromide, and visualized under 
UV illumination.
Chemotherapeutic drugs and adjuvant molecules
Temozolomide, ETO and IRI (Sigma-Aldrich, Saint Louis, 
MO, USA) were dissolved in dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich) at the concentration of 100 mM, 30 mg/
mL and 10  mg/mL, respectively, while CARB and LEV 
(Sigma-Aldrich) were dissolved in deionized water at the 
concentration of 10  mg/mL and 5  mg/mL, respectively. 
All the drugs were stored as stock solutions at -80 °C and 
diluted in stem cells culture medium just before use. The 
final drug concentrations used in the experiments were: 
TMZ: 250 µM; ETO: 10 µM; IRI: 10 µg/mL and CARB: 
10 µg/mL; LEV: 40 µg/mL.
When the cells were treated with both TMZ and LEV, 
LEV was added 2 h before TMZ addition and the cultures 
were stopped after 48 h. The chemotherapeutic drug con-
centrations utilized in our experiments are in the higher 
range of serum peak levels transiently reached in  vivo 
during high-dose chemotherapy.
BrdU cell proliferation assay
GCSCs and PCSCs were seeded at the density of 50.000 
cells/well in 96-well plates and incubated overnight. The 
cells were then treated with the appropriate chemothera-
peutic agents, as indicated in the Fig. 1 for 48 h. Finally 
10 µM BrdU was added to the plates and the cells were 
incubated overnight. BrdU proliferation assay was per-
formed according to the manufacturer’s instructions 
(Cell Signaling, #6813 Danvers, MA, USA).
Western blot analysis
For immunoblotting analysis, cells were washed in 
1 × PBS, harvested and lysed in 1x Cell Lysis Buffer (Cell 
Signaling #9803) containing 1  mM PMSF (Cell Signal-
ing #8553) and a complete protease inhibitor cocktail 
(Cell Signaling #5872) for 30 min at 4 °C. Then the cells 
were sonicated briefly and the extracts were centri-
fuged 10  min at 14,000 × g in a cold microfuge. Protein 
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concentration was determined by Bradford Protein Assay 
(Bio-Rad Laboratories Inc, Hercules, CA, USA) accord-
ing to the manufacturer’s instructions. Equal amounts 
of proteins were then separated by SDS/PAGE (Mini-
PROTEAN® TGX™ Precast Protein Gels, or Mini-
PROTEAN TGX stain-free precast PAGE gels, Bio-Rad 
Laboratories Inc.) and transferred to a nitrocellulose 
membrane (GE Healthcare, Piscataway, NJ, USA). Mem-
branes were blocked with Tris-buffered saline (TBS) 1X 
(Bio-Rad Laboratories Inc.) supplemented with 0.1% 
Tween-20 and containing 5% nonfat milk for 1 h at room 
temperature (RT). The primary antibodies used in this 
work  were: anti-MGMT (1:500, mouse monoclonal anti-
body, clone MT3.1, MAB16200, Merk Millipore, Darm-
stadt, Germany); anti-HDAC4 (1:100, rabbit monoclonal 
antibody, sc-46672 Santa Cruz Biotechnology, Dallas, Tx, 
USA); anti-PCNA (1:1000, mouse monoclonal antibody, 
M0879, Dako, Santa Clara, CA, USA); anti-cleaved Cas-
pase-3 (1:1000, polyclonal antibody, #9665, Cell Signal-
ing); anti-β-actin, (1:10000 mouse monoclonal antibody, 
Sigma-Aldrich). Blots were then incubated with horse-
radish peroxidase-conjugated secondary antibody 
(1:10,000, Vector Laboratories, Burlingame, CA, USA) 
for 1 h RT. Signals were captured by ChemiDoc™ Imaging 
System (Bio-Rad Laboratories, Hercules, CA, USA) using 
an enhanced chemiluminescence system (SuperSignal 
Chemoluminescent substrate, Thermo Fisher Scientific 
Inc. Waltham, MA, USA) and densitometric analyses 
were performed with Image Lab™ Touch Software (Bio-
Rad Laboratories). Nuclear and cytosolic fractions were 
normalized using stain free technology (Bio-Rad Labora-
tories Inc.). All experiments were carried out in triplicate 
and representative results are shown.
Immunofluorescence and confocal microscopy analysis
Immunofluorescence analysis was performed on GCSCs 
and PCSCs collected onto a glass slide using a Cyto-
spin centrifuge (Shandon Centrifuge, Model Cytospin 3, 
Marshall Scientific, Hampton, NH, USA), fixed with 4% 
paraformaldehyde for 20 min, incubated with 0,01% Tri-
ton X-100 for 7 min and blocked with Super Block solu-
tion (UCS Diagnostic S.r.l., Morlupo, Italy) for 5 min. The 
slides were incubated overnight at 4 °C with the primary 
antibodies against: MGMT (1:100, Merk Millipore), 
HDAC4 (1:100; Santa Cruz Biotechnology, INC.) and 
cleaved Caspase-3 (1:400, Cell Signaling). The next day, 
the slides were incubated with the following secondary 
antibodies for 1 h at RT: Alexa Fluor 584 (1:1000, Invit-
rogen Molecular Probes, Eugene, OR, USA) and Alexa 
Fluor 488 (1:1000, Invitrogen Molecular Probes). The 
cells were cover-slipped with ProLong Gold antifade rea-
gent with DAPI (Life Technologies) and examined with 
a confocal laser scanning microscope (TCS-SP2, Leica 
Microsystems, GmbH, Wetzlar, Germany) equipped with 
an Ar/ArKr laser and a HeNe lasers. The images were 
recovered utilizing the Leica Confocal software. Laser 
line was at 488 nm and 543 for alexafluor 488 and alex-
afluor 568 excitation, respectively. For each analyzed 
field, optical spatial series each composed of about 10 
optical sections with a step size of 1 μm were obtained. 
The images were scanned under a 40× oil. In each exper-
iment, negative controls without the primary antibody 
were included to check for nonspecific staining.
Statistical analysis
Each experiment was repeated three times. Data are pre-
sented as the mean ± SD. Statistical analysis was generally 
performed using Student’s t-test, assuming equal variance, 
and p-values were calculated based on the 2-tailed test. A 
p-value of < 0.05 was considered statistically significant. 
The Mann-Whitney test was used for the analysis of dis-
tribution values of BrdU incorporation in neurospheres.
Results
TMZ was the less effective chemotherapeutic agent 
in decreasing the GCSC and PCSC proliferation
The analysis of the IDH1 status in all the GCSC and 
PCSC pairs derived from six patients revealed that all of 
Fig. 1 Effects of chemotherapeutic treatments on patient-derived GSC proliferation. GCSC and PCSC neurospheres derived from GBM of six 
different patients were treated with TMZ (250 µM), ETO (10 µM), IRI (10 µg/mL) and CARB (10 µg/mL) for 48 h. GCSCs and PCSCs proliferation rate 
was evaluated by BrdU incorporation. a The graph represents the distribution values of BrdU incorporation of the all neurospheres analyzed. b 
The graph represents BrdU incorporation of the GCSCs and PCSCs derived from patients #1, #2 and #3, that exhibit a higher capacity of BrdU 
incorporation. c The graph represents BrdU incorporation of the GCSCs and PCSCs derived from patients #4, #5 and #6, that exhibit a lower capacity 
of BrdU incorporation. K-means algorithm was used to cluster into 2 groups the BrDU incorporation values. d Percentage of decreased BrdU 
incorporation versus CTR. The results shown are representative of three independent experiments. a–c *p < 0.05 vs CTR by Mann–Whitney test. d 
* p< 0.05, ** p< 0.01, ***p < 0.001 vs CTR by Student’s t-test
(See figure on next page.)
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them are IDH1-wildtype. Moreover, the analysis of muta-
tional IDH1/2 status and MGMT promoter methylation 
status in all the available tissue samples revealed that all 
of them were IDH1/2 wildtype and showed an un-meth-
ylated MGMT status.
We then investigated the effects of different chemo-
therapeutic agents on the proliferation of the neu-
rospheres isolated from the GBM derived from six 
different patients. For this purpose, GCSCs and PCSCs 
were treated with TMZ, ETO, IRI and CARB for 48  h 
and then the rate of proliferating cells was evaluated by 
BrdU incorporation. At first, we noted that when the 
data regarding GCSCs and PCSCs derived from all the 
patients were analyzed together they were distributed 
in two clusters: one with the higher and one with lower 
values of BrdU incorporation (Fig.  1a). Interestingly, all 
the chemotherapeutic agents exerted significant effects 
only in the cells with higher values of BrdU incorpora-
tion (GCSCs and PCSCs derived from patients #1, #2 
and #3) (Fig. 1b), whereas none of the drugs affected sig-
nificantly the cells with a lower proliferation rate (GCSCs 
and PCSCs derived from patients #4, #5 and #6) (Fig. 1c). 
We then evaluated, more specifically, the percentage of 
proliferative reduction induced by the chemotherapeutic 
agents when the GCSCs and the PCSCs derived from the 
GBM of each patient were considered separately (Fig. 1d). 
As expected, both GCSCs and PCSCs obtained from the 
GBM of all the patients exhibited a higher resistance in 
terms of proliferation to the chemotherapeutic drug 
treatments when compared to Jurkat cells that, as hemat-
opoietic cells, represent a good general model to test 
chemotherapeutic agent activity [36] (Additional file  1 
and Additional file  2: Figure S1). Although no signifi-
cant differences were observed in the response between 
GCSCs and PCSCs, our results showed that, similarly 
to what happens in Jurkat cells, TMZ had the lower 
effect, as demonstrated by the percentage of decreased 
proliferative range (8–23% versus CTR), while CARB had 
the stronger effect since the percentage of decreased pro-
liferative range was 21–45% versus CTR (Fig. 1d).
Levetiracetam sensitized GSCs to TMZ treatment
Since our previous results demonstrated that, among 
the tested antineoplastic drugs, TMZ was the less effi-
cient to decrease the proliferation of both GCSCs and 
PCSCs, we then investigated whether its anti-prolifera-
tive effect might be strengthened when combined with 
the LEV. LEV concentration used in this study (40  μg/
mL) is included in the clinical serum therapeutic con-
centration range achieved in patients at oral doses of 
500-1000  mg twice daily [28]. GCSCs and PCSCs iso-
lated from the GBM derived from six patients were 
treated with TMZ, LEV or with a combination of TMZ 
and LEV, for 48 h. Figure 2a shows that, when analyzed 
together, the GCSCs derived from all the patients dis-
played a significant reduction of BrdU incorporation only 
with the combined treatment with TMZ and LEV. This 
result is confirmed by the analysis of BrdU incorpora-
tion evaluated in the GCSCs derived from each patient 
(Fig.  2b), demonstrating that the slight antitumor effect 
exerted by the treatment with  TMZ or LEV alone was 
strongly enhanced when TMZ and LEV were added in 
combination. Only the GCSCs derived from patient #6 
did not display a significant reduction in cell proliferation 
(Fig. 2b). Interestingly, the PCSCs subjected to the same 
treatments (Fig. 3a, b) seemed to be more resistant than 
the GCSCs since only the PCSCs derived from patients 
#4 and #5 (Fig. 3b) showed a significant decrease of pro-
liferation when exposed to the combination of TMZ and 
LEV compared to either untreated cells or treated with 
these drugs alone. These results demonstrate that LEV 
sensitized GBM stem cells to TMZ and that this effect is 
stronger in GCSCs than in PCSCs. 
(See figure on next page.)
Fig. 2 Effect of TMZ and LEV combined treatment on GCSC proliferation. GCSC neurospheres derived from GBM of six different patients were 
treated with TMZ (250 µM), LEV (40 μg/mL) or with a combination of TMZ and LEV for 48 h. Cell proliferation was evaluated by BrdU incorporation. 
The results were representative of three independent experiments. Statistical analysis was performed using Mann–Whitney test *p < 0.05 (a) and 
Student’s t-test (b). P value < 0.05 was considered statistically significant
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MGMT expression was downregulated in GCSCs treated 
with LEV + TMZ
To test the hypothesis that LEV-induced sensitization to 
TMZ might result from the inhibition of MGMT-medi-
ated DNA repair, we investigated MGMT protein levels. 
This analysis was performed in the GCSCs derived from 
patient #4, which displayed a high reduction of the pro-
liferative rate after exposure to the combined treatment 
with LEV + TMZ and in PCSCs derived from patient #6, 
which showed resistance to all the treatments. The data 
obtained by BrdU cell proliferation assay were confirmed 
by Western blot analysis shown in Figs.  4c, d and 5c, d 
that demonstrated a decreased expression of the prolif-
eration marker PCNA in the GCSCs of patient #4 when 
LEV and TMZ were added together, while its expression 
was not affected in the PCSCs derived from patient #6. 
Western blot analysis revealed a high level of MGMT 
expression in untreated GCSCs derived from patient 
#4; this expression was slightly decreased after treat-
ment with TMZ and LEV singularly but it was dramati-
cally decreased after the combined treatment with TMZ 
and LEV (Fig. 4a, b). In contrast, none of the treatments 
seemed to modify the MGMT expression level in the 
PCSCs derived from patient #6 when compared with 
untreated cells (Fig. 5a, b). Immunofluorescence analysis 
confirmed that the high expression of MGMT in con-
trol GCSCs derived from patient #4 (Fig.  4e) was par-
tially decreased in the presence of either LEV or TMZ, 
while it was strongly reduced by the combined treat-
ment with TMZ and LEV (Fig. 4e). In contrast, none of 
the treatments modified MGMT expression in PCSCs 
derived from the GBM of patient #6 (Fig. 5e). The PCNA 
and MGMT expression levels were also investigated in 
the PCSCs derived from patient #2 that similarly to the 
PCSCs of patient #6 did not show a reduction of the pro-
liferative rate after exposure to all the treatments. West-
ern blot analysis revealed that none of the treatments 
significantly affected the MGMT expression level, and 
the slight effect of TMZ and LEV on PCNA expression 
was not significantly modified by the combined treat-
ment with TMZ + LEV (data not shown). 
LEV induced HDAC4 nuclear translocation in TMZ‑treated 
GCSCs but not in PCSCs
It is has been demonstrated that some antiepileptic 
drugs, such as LEV, are able to regulate the HDACs activ-
ity. In particular, HDACs inhibitors can influence TMZ 
efficacy by modulating the expression of MGMT. Hence, 
we verified whether in our system, the LEV-induced 
sensitization to TMZ might be the result of a HDACs-
dependent mechanism.
To this purpose, we first analyzed the expression lev-
els and the cellular localization of HDAC4 in the GCSCs 
derived from patient #4, that, as we previously demon-
strated, greatly reduced their proliferative rate following 
the combined treatment with TMZ and LEV, in com-
parison with the PCSCs derived from patient #6, that, 
by contrary, showed resistance to the same treatment. 
Immunofluorescence analysis (Fig.  6A) and Western 
blotting of nuclear and cytosolic fractions (Fig.  6B, C) 
revealed that the combination of TMZ and LEV induced 
the accumulation of HDAC4 into the nucleus of GCSCs 
derived from patient #4. Indeed HDAC4 expression was 
low and diffuse in the control and in correspondence of 
the separate treatments (Fig. 6A: panel a, b and c) while 
a strong nuclear expression was detected in TMZ + LEV 
treated cells (Fig. 6: panel d).
Interestingly, none of the treatments induced HDAC4 
nuclear translocation in PCSCs derived from patient #6 
as demonstrated by the immunofluorescence and West-
ern Blotting of nuclear and cytosolic fractions, as shown 
in Fig.  6D–F. We also performed Western blot analysis 
of HDAC4 expression in the total lysate of the PCSCs 
derived from patient #2 subjected to the same treatments 
described above, demonstrating that the low increase in 
HDAC4 expression observed after TMZ treatment was 
Fig. 3 Effect of TMZ and LEV combined treatment on PCSC proliferation. PCSC neurospheres derived from GBM of six different patients were 
treated with TMZ (250 µM), LEV (40 μg/mL) or with a combination of TMZ and LEV for 48 h. Cell proliferation was evaluated by BrdU incorporation. 
The results were representative of three independent experiments. Statistical analysis was performed using Mann–Whitney test *p < 0.05 (a) and 
Student’s t-test (b). P value < 0.05 was considered statistically significant
(See figure on next page.)
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not significantly modified by the combined treatment 
with TMZ and LEV (data not shown).
LEV induced apoptosis in TMZ‑treated GCSCs but not in 
PCSCs
It has been demonstrated that one of the mechanisms 
involved in the cytotoxic effect of chemotherapeutic 
agents is apoptosis. Indeed, in Jurkat cells, all the chem-
otherapeutic treatments significantly induced high lev-
els of the activity of some of the pro-caspases that are 
known to act as initiators (such as Caspases-2, -8 and 
-9) and some of the caspases (such as Caspase-3 and 
-6) that are known to act as effectors of apoptosis (IRI 
treatment only did not significantly induce the activity 
of Caspase-6) (Additional file  1 and Additional file  3: 
Figure S2). To explore whether the anti-proliferative 
effect of the combined treatment with TMZ and LEV 
was associated with apoptotic death, we tested for the 
presence and cellular localization of cleaved Caspase-3 
under the same condition described above. By immu-
nofluorescence analysis, we observed that in the GCSCs 
derived from patient #4, Caspase- 3 is present in the 
cytoplasm of the control and of the cells that received 
the individual treatments with LEV or TMZ (Fig.  7A: 
panels a–c), while its expression was strongly increased 
in the nuclei when the cells received the combined treat-
ment LEV + TMZ (Fig.  7A: panel d). To confirm this 
result, we assessed the levels and the intracellular locali-
zation of cleaved Caspase-3 by Western blot analysis of 
nuclear and cytosolic fraction. Figure  7B and C show 
that Caspase-3 expression was significantly increased in 
the nuclei of GCSCs of patient #4 when the cells were 
treated with TMZ and LEV together, while none of the 
treatments exerted Caspase-3 significant modifications 
in cytosolic extracts. In contrast, immunofluorescence 
and Western blot analysis performed on PCSCs derived 
from patient #6 demonstrated that although low levels 
of Caspase-3 were detected in both nuclei and cytosolic 
fractions, none of the treatments induced changes in its 
expression (Fig. 7D–F). Caspase- 3 expression was also 
evaluated by Western blot analysis in the total lysate of 
the PCSCs derived from patient #2. Although a slight 
but significant increase in the Caspase-3 expression 
was detectable after TMZ treatment, this effect was not 
modified by the combined treatment with TMZ + LEV 
(data not shown).
Discussion
Glioblastoma is a very aggressive form of brain tumor 
particularly resistant to the standard therapies which 
include maximal surgical resection, followed by com-
bined treatment with radiotherapy and chemotherapy 
[6]. Alkylating agents, such as TMZ and CARB, and 
topoisomerase inhibitors, such as ETO and IRI, although 
effectively improve clinical outcomes when used alone or 
in combination with radiotherapy, display several adverse 
effects [6] and their administration has not significantly 
changed the survival for GBM over the last years, making 
chemoresistance one of the biggest problems for GBM 
therapy [37]. Thus, it is evident the need to identify new 
therapeutic strategies that can increase the life spans of 
patients affected by GBM.
Glioblastoma stem-like cells (GSCs) represent a sub-
population within the heterogeneous tumor mass of 
GBM, with a high similarity with neural stem cells [6, 38]. 
They are characterized by elevated proliferative rate and 
tumorigenic capability in  vivo [39, 40] and are thought 
to be responsible for the resistance to standard therapies 
[41, 42]. It has been demonstrated that the peritumor tis-
sue is the site of tumor recurrence in 90% of the patients 
[19]. This area shows complex changes such as edema, 
increased vascularization, abnormal gene expression and 
presence of numerous specialized cell types  [13–18], 
and is also the site in which a subpopulation of cancer 
stem-like cells (PCSCs) has been found [12]. Although 
both GCSCs and PCSCs express stem cell markers, they 
have different characteristics in terms of self-renewal and 
(See figure on next page.)
Fig. 4 LEV effect on MGMT expression in GCSCs. GCSCs derived from patient #4 were treated with TMZ (250 µM), LEV (40 μg/mL) and with a 
combination of TMZ and LEV for 48 h. a, c Western blot analysis of MGMT and PCNA expression levels; representative immunoblots are shown. b, 
d Densitometric analysis of MGMT and PCNA expression levels (normalized to β-actin levels) of three independent experiments. Statistical analysis 
was performed using Student’s t-test. P value < 0.05 was considered statistically significant. e Confocal microscopy micrographs of GCSCs from 
patient #4 showing MGMT expression. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Original magnification: ×400
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Fig. 5 LEV effect on MGMT expression in PCSCs. PCSCs derived from patient #6 were treated with TMZ (250 µM), LEV (40 μg/mL) and with a 
combination of TMZ and LEV for 48 h. a, c Western blot analysis of MGMT and PCNA expression levels; representative immunoblots are shown. b, 
d Densitometric analysis of MGMT and PCNA expression levels (normalized to β-actin levels) of three independent experiments. Statistical analysis 
was performed using Student’s t-test. P value < 0.05 was considered statistically significant. e Confocal microscopy micrographs of PCSCs from 
patient #4 showing MGMT expression. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Original magnification: X 400
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tumorigenicity, suggesting that PCSCs may have high rel-
evance in translational research [12].
In this study, we investigated the response of IDH1-
wildtype GCSCs and PCSCs derived from six patients 
affected by GBM to different chemotherapeutic drugs 
and verified the possibility to enhance their effect 
through the combined treatment with adjuvant mol-
ecules. The comparison of GCSCs and PCSCs behavior 
and the identification of the molecules involved in their 
differential response to the treatments may provide a 
further insight in the complexity of GBM-neighboring 
microenvironment, which plays a crucial role in tumor 
progression.
Since hematopoietic cells represent the primary tar-
get of chemotherapy-related adverse effects, here we 
first analyzed the efficacy of different chemotherapeutic 
drugs (TMZ, ETO, IRI and CARB) in Jurkat cells (Addi-
tional file  2: Figure S1A). As expected, all the tested 
antineoplastic agents dramatically decrease the prolif-
eration of these cells. In particular, BrdU assay dem-
onstrates that IRI and CARB have the stronger effect 
in decreasing proliferation while TMZ is less efficient. 
Western blot analysis of PCNA expression confirms 
that among the used compounds, TMZ exerts the lower 
anti-proliferative activity (Additional file 2: Figure S1B 
and C). This effect seems to be related to the activation 
of apoptotic pathway since all the chemotherapeutic 
drugs increased the activity of both pro- and effector-
caspases (Additional file  3: Figure S2). We then inves-
tigated the effects of the different chemotherapeutic 
treatments on the proliferation rate of GCSCs and 
PCSCs. Both cell populations resulted more resist-
ant than Jurkat cells to the different treatments and 
we noted that all the chemotherapeutic agents exerted 
significant effects only in the cells with higher values of 
BrdU incorporation (GCSCs and PCSCs derived from 
patients #1, #2 and #3), whereas none of the drugs 
affected significantly the cells with a lower prolifera-
tion rate (GCSCs and PCSCs derived from patients 
#4, #5 and #6). Moreover, although no significant dif-
ferences  have been found between GCSCs and PCSCs, 
TMZ is the drug with the lower efficacy in decreas-
ing the proliferation of neurosphere clones derived 
from GBM of all the six patients. TMZ is a small mol-
ecule that is readily absorbed in the digestive tract 
and, because of its lipophilia, it is able to cross the 
blood–brain barrier. TMZ is the most widely chemo-
therapeutic drug used in patients with GBM, although 
the majority of the patients demonstrate de novo or 
acquired resistance, with subsequent tumor progres-
sion [5, 43]. Thus, the identification of the mechanisms 
of resistance and the attempting to enhance its effect 
can represent a good therapeutic strategy. MGMT 
repairs cytotoxic DNA lesions generated by TMZ. 
Many studies have shown a mechanistic link between 
MGMT activity and TMZ resistance, with suppression 
of MGMT activity resulting in increased cytotoxic-
ity and MGMT protein overexpression which lead to 
resistance [31]. However, the role of MGMT in the evo-
lution of acquired resistance is not well established as 
demonstrated by several papers revealing that MGMT 
expression is not always related to resistance to TMZ 
treatment [44–46]. Since our results demonstrate that 
TMZ is the less efficient chemotherapeutic agent in 
decreasing the proliferation of both GCSCs and PCSCs, 
we have investigated the possibility of increasing its 
anti-tumor activity by means of the combined use with 
LEV. LEV is a relatively new non-enzyme inducing AED 
(See figure on next page.)
Fig. 6 LEV effect on HDAC4 expression in GCSCs and PCSCs. GCSCs from patient #4 and PCSCs from patient #6 were treated with TMZ (250 µM), 
LEV (40 μg/mL) and a combination of TMZ and LEV for 48 h. A panels a–d HDAC4 expression was evaluated in GCSCs from patient #4 by 
immunofluorescence analysis. Confocal microscopy micrographs showing HDAC4 (green) in untreated control cells (a), TMZ treated cells (b), 
LEV treated cells (c) and LEV + TMZ treated cells (d). B Cytoplasmic and nuclear extracts from GCSCs (patient #4) were evaluated for HDAC4 
expression by Western blot analysis. A representative immunoblot is shown. C Densitometric analysis of HDAC4 expression levels of three 
indipendent experiments normalized using Stain free technology. Statistical analysis was performed using Student’s t-test. P value < 0.05 was 
considered statistically significant. D panels a–d HDAC4 expression was evaluated in PCSCs from patient #6 by immunofluorescence analysis. 
Confocal microscopy micrographs showing HDAC4 (green) in untreated control cells (a), TMZ treated cells (b), LEV treated cells (c) and LEV + TMZ 
treated cells (d). E Cytoplasmic and nuclear extracts from PCSCs (patient #6), were evaluated for HDAC4 expression by Western blot analysis. A 
representative immunoblot is shown. F Densitometric analysis of HDAC4 expression levels of three indipendent experiments normalized using 
Stain free technology. Statistical analysis was performed using Student’s t-test. P value < 0.05 was considered statistically significant
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strongly recommended as a first line drug for patients 
with brain tumors [47]. Recently, a growing body of 
evidence suggests that selected AEDs could lead to sig-
nificant pharmaco-epigenetic interactions. It has been 
reported that LEV could act by favoring the recruit-
ment of inhibitory complex, including HDAC, on the 
MGMT promoter, thus reducing its transcription [25]. 
Here we show that in the GCSCs the combined treat-
ment with LEV and TMZ decreases the MGMT expres-
sion levels and induces the nuclear translocation of 
HDAC4, suggesting, in agreement to what reported 
by Bobustuc et  al. [25], an HDAC4-dependent inhibi-
tory role for MGMT transcription, thus increasing the 
sensitivity of these cells to TMZ treatment. In contrast, 
HDAC4 is expressed, although at low levels, in PCSCs, 
but none of the treatments modulated its expres-
sion and cellular localization. As GSCs show intrinsic 
deregulation in apoptotic cell death, we investigated 
whether in our system, the decreased proliferation rate 
observed in the presence of the combined treatment 
with LEV and TMZ could be associated with the activa-
tion of apoptotic pathway. Here we show an increased 
caspase 3 nuclear accumulation in GCSCs, while no 
change of its expression was observed in PCSCs. This 
result is supported by the analysis of pro-and effector-
caspase expression evaluated in Jurkat cells after expo-
sure to different chemotherapeutic agents showing 
that all the treatments significantly induced high levels 
of the activity of both classes of caspase compared to 
untreated cells (Additional file  3: Figure S2). All these 
data suggest that activation of apoptotic pathway is 
involved in the strong anti-proliferative effect exerted 
by the used antineoplastic drugs.
Taken together our results demonstrate that LEV 
enhances the TMZ effect on GCSCs by HDAC4-depend-
ent downregulation of MGMT and by the activation of 
apoptotic pathways. PCSCs seem to be more resistant 
to the treatment, suggesting that the peritumoral micro-
environment can favor the activation of survival mecha-
nisms that make this therapeutic approach less effective. 
Our results are supported by data reported by Kim et al. 
demonstrating that the median progression-free sur-
vival and overall survival for patients who received LEV 
in combination with TMZ were significative longer than 
those for patients who did not receive LEV [48]. In addi-
tion, a case report was published by Peddi et  al. where 
a continuous regression of GBM was noted in a patient 
who received LEV and Dexamethasone without any can-
cer-targeted therapy, suggesting that the response may 
be related to Dexamethasone and/or LEV treatment [49]. 
Although more studies are needed to better evaluate the 
role of LEV and its molecular mechanism of action, these 
papers together with our results strongly suggest the ben-
eficial effect of LEV as a chemosensitizer agent.
Conclusions
Although further studies are necessary to better charac-
terize the GSC environment, our results suggest that the 
clinical therapeutic efficacy of TMZ in GBM might be 
potentiated by the combination treatment with LEV and 
Fig. 7 LEV effect on Caspase-3 expression in GCSCs and PCSCs. GCSCs from patient #4 and PCSCs from patient #6 were treated with TMZ 
(250 µM), LEV (40 μg/mL) and a combination of TMZ and LEV for 48 h. A panels a–d Caspase-3 expression was evaluated in GCSCs from patient 
#4 by immunofluorescence analysis. Confocal microscopy micrographs showing Caspase-3 (green) in untreated control cells (a), TMZ treated 
cells (b), LEV treated cells (c) and LEV + TMZ treated cells (d). B Cytoplasmic and nuclear extracts from GCSCs (patient #4) were evaluated for 
Caspase-3 expression by Western blot analysis. A representative immunoblot is shown. C Densitometric analysis of Caspase-3 expression levels of 
three indipendent experiments normalized using Stain free technology. Statistical analysis was performed using Student’s t-test. P value < 0.05 
was considered statistically significant. D panels a–d Caspase-3 expression was evaluated in PCSCs from patient #6 by immunofluorescence 
analysis. Confocal microscopy micrographs showing Caspase -3 (green) in untreated control cells (a), TMZ treated cells (b), LEV treated cells (c) 
and LEV + TMZ treated cells (d). E Cytoplasmic and nuclear extracts from PCSCs (patient #6) were evaluated for Caspase-3 expression by Western 
blot analysis. A representative immunoblot is shown. F Densitometric analysis of Caspase-3 expression levels of three indipendent experiments 
normalized using Stain free technology. Statistical analysis was performed using Student’s t-test. P value < 0.05 was considered statistically 
significant
(See figure on next page.)
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that the enhancement of apoptotic pathways may repre-
sent a primary goal in the development of new and more 
effective strategies.
Additional files
Additional file 1. Description (Results, Material and Methods) of addi-
tional figures S1 and S2.
Additional file 2: Figure S1. Effects of different chemotherapeutic drugs 
on Jurkat cell proliferation. (A) BrdU cell proliferation assay of Jurkat cells 
treated for 48 h with TMZ (250 µM), ETO (10 µM), IRI (10 µg/ml) and CARB 
(10 µg/ml). (B) Western blot analysis of total lysates from Jurkat cells, 
treated as described above was performed to detect PCNA expression 
levels; β-actin was used as a loading control. (C) Densitometric analysis 
of three independent experiments on PCNA expression levels. ** p< 0.01, 
***p < 0001 vs control by Student’s t-test.
Additional file 3: Figure S2. Effects of different chemotherapeutic agents 
on apoptosis induction in Jurkat cells. Jurkat cells were treated with the 
same concentrations of the antineoplastic drugs described in additional 
Fig. 1. After 48 h, the activity of the pro-caspases-2, -8 and -9 and of the 
effector caspases -3 and -6 was measured by using ApoTarget Caspase 
Colorimetric Protease Assay. The results are representative of three 
independent experiments. *p < 0.05, **p < 0.01, ***  p< 0.001 vs control by 
Student’s t-test.
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